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Overall, clinicians’ preferences for drugs delivered via intrathecal pumps were 
driven by patient-related health factors.
PND57
Barriers To PrescriBiNg MeDicaTioNs To PaTieNTs WiTh MulTiPle 
sclerosis: a coMParisoN of healTh care ProviDer PercePTioNs iN 
euroPeaN uNioN (eu) aND The uNiTeD sTaTes
Narayanan S.1, Khan H.2, Gabriele S.2, White J.2
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Objectives: To assess health care provider (HCP) perception of barriers to pre-
scribing medications to patients with Multiple Sclerosis (MS) in EU and the 
US. MethOds: A multi-country HCP survey was conducted in 5EU (UK/Germany/
France/Spain/Italy) and the US as part of a retrospective chart-review study of MS 
patients. HCPs (mostly physicians) were screened for experience (> = 3yrs) and 
patient volume (> 15MS patients/month) and recruited from a large HCP-panel to 
be geographically representative in each country. Practice characteristics, HCP per-
ceptions and practice patterns were assessed. HCP perceptions of the following 
barriers to prescribing interferons (all types), glatiramer acetate, natalizumab and 
fingolimod were assessed: patients prefer other medications (barrier-1), availability/
cost (barrier-2), guidelines/license restrictions (barrier-3) and drug-related issues 
(barrier-4). Summary statistics are reported. ResULts: In 4Q2012, 360 HCPs (nerol-
ogists:95%; nurses:5% (from UK only)) participated. Mean age (5EU/US):45/50yrs; 
female (5EU/US):34%/21%; years practicing in neurology (5EU/US):16/19yrs; practice-
location (> = 50% of time in hospital-setting; 5EU/US):83%/26%; % HCPs seeing MS 
patients in specialty clinic (5EU/US):53%/27%; % HCPs with MS as the main focus 
area (5EU/US):68%/40%. Geographic distribution of HCPs was: 5EU-72% (UK-16%, 
Germany/France/Spain/Italy-14% each), US-28%. Patient volume/month per HCP 
was (5EU/US): All-patients-254/319, MS-patients-61/68. MS patient-type seen was 
(5EU/US): relapsing-remitting-52%/58%, relapsing secondary progressive-13%/13%, 
non-relapsing secondary progressive-13%/12%, primary progressive-8%/6%, clini-
cally isolated syndrome-9%/7%, benign-6%/4%. Average prescriptions written/month 
for MS-treatments was (5EU/US):51/62. Key barriers to prescribing interferons were 
(5EU/US): barrier-1:12%/13%, barrier-2:11%/21%, barrier-3:9%/8%, barrier-4:55%/56%, 
no-barrier:30%/24%; for glatiramer (5EU/US): barrier-1:14%/12%, barrier-2:9%/18%, 
barrier-3:8%/6%, barrier-4:62%/60%, no-barrier:28%/28%; for natalizumab (5EU/
US): barrier-1:16%/17%, barrier-2:28%/36%, barrier-3:47%/23%, barrier-4:81%/92%, 
no-barrier:15%/5%; for fingolimod (5EU/US): barrier-1:5%/21%, barrier-2:35%/48%, 
barrier-3:49%/21%, barrier-4:65%/84%, no-barrier:17%/4%. cOncLUsiOns: Drug-
related issue was the most frequently cited barrier to prescribing MS medications 
both in 5EU and the US. Drug availability/cost and guidelines/license restrictions 
were more often cited by HCPs in the US and 5EU respectively. Impact of these bar-
riers on optimal patient management and outcomes may warrant further research.
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Objectives: The purpose of this study was to understand how United States payers 
manage novel oral, high cost MS medications in consideration of the availability of 
lower cost injectable treatments, generally considered less convenient regarding 
administration while in line with the efficacy of orals. MethOds: The respective 
tier statuses and utilisation management of teriflunomide, fingolimod, dimethyl 
fumarate, interferon beta-1a (AVONEX and REBIF), and glatiramer acetate at 46 plans 
were audited: 18 Medicare, 12 national private (including PBMs), and 16 regional 
and state private plans. Access to oral MS treatments was compared to that of 
injectable MS treatments to identify differences in tiering or utilisation manage-
ment. ResULts: 54% of plans demonstrated preferential coverage of injectable MS 
therapies over orals, by lower tier status or lighter utilisation management. By seg-
ment, regional and state private plans demonstrated the strongest preference for 
injectables, with 75% of these plans demonstrating this preference compared to 50% 
of Medicare and 33% of national private plans. Plans employing prior authorisation 
or step edits to manage oral MS therapies usually stepped orals through injectables. 
Among oral MS products, national private and Medicare plans tended to prefer 
fingolimod, with 50% and 61% of plans preferring it over at least one other oral MS 
product, respectively. 19% of regional and state private plans preferred dimethyl 
fumarate over at least one other oral MS product. cOncLUsiOns: United States pay-
ers take varying approaches to the management of oral MS medications; however, 
virtually no plans offer preferential access to orals over injectables. The sample is 
roughly split between plans preferring injectable MS products over orals and those 
offering roughly parity access.
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Objectives: Cleft lip with and without cleft palate is the second most prevalent 
birth defect in the United States. Previous epidemiological studies of cleft lip surgery 
have been plagued by multiple design and methodological issues, including failure 
to adjust costs, grouping of cleft lip only (CL) with cleft lip and palate (CLP) diagno-
ses, and improper definition of secondary cleft lip surgery. The objective of this study 
was to provide national estimates of primary and secondary cleft lip surgery using 
cohort definitions based on national treatment guidelines. MethOds: The nation-
ally representative Kids’ Inpatient Database (KID) was used for this study. Years 
analyzed included 2003, 2006, and 2009. Subjects were identified by International 
Classification of Diseases Ninth Revision (ICD-9) diagnosis of cleft lip only or cleft 
lip and palate. Primary surgery was defined as a surgery before two years of age with 
the ICD-9 procedural code for cleft lip repair. Secondary surgery was defined as a sur-
Objectives: The Ontario Drug Policy Research Network has received provincial gov-
ernment funding to conduct research relating to formulary modernization within 
the Ontario Public Drug Programs. This innovative, integrated program for drug 
class reviews incorporates a novel methodological technique called reimbursement-
based economics which focuses on reimbursement strategies. The first class review 
related to triptans for migraines. In Ontario, triptans are currently available through 
the Exceptional Access Program (EAP). Specific research questions related to the 
current evidence for the cost-effectiveness of triptans and the economic impact 
of alternative changes to their funding status. MethOds: Systematic review of 
cost-effectiveness studies of triptans focusing on strength and quality of evidence. 
2. Applied, policy-oriented reimbursement based economic model developed to 
forecast budget expenditure for each alternative reimbursement strategy (generic 
pricing, generic substitution, quantity limits and/or more liberal access). ResULts: 
21 economic studies were identified though many had a number of common limita-
tions reducing their usefulness in aiding decision making. The weight of evidence 
suggests that triptans are more cost effective than ergots, in patients experienc-
ing acute migraine. Maintaining triptans within the EAP with generic equivalents 
costing 25% of branded products reduces expenditure by 18%-85%. Greater access 
to triptans but with a quantity limit of 6 units per month would increase total 
expenditure by between 133%-140%: less restrictive quantity limits would lead to 
expenditure increases of up to 326%. cOncLUsiOns: Evidence suggests that, for 
migraine, triptans are cost effective compared to ergots. Allowing greater access to 
triptans would significantly increase expenditure and may lead to use in a wider 
population where neither effectiveness nor cost effectiveness has been established. 
Maintaining triptan coverage through EAP with generic equivalents costing 25% of 
branded products combined with generic substitution will reduce total expendi-
tures by 67%. Other factors will be considered before final recommendations on 
formulary changes are made.
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aND TheN There Were Three; The BurgeoNiNg MarKeT of oral 
MeDicaTioNs aPProveD To TreaT MulTiPle sclerosis iN The uNiTeD 
sTaTes
Johnson B.H.
Truven Health Analytics, Cambridge, MA, USA
Objectives: The first oral disease modifying therapy (DMT) was approved in the fall 
of 2010, the second followed two years later with a short six-month gap before the 
third approval. This study sought to describe and compare patients prescribed one 
of the three oral DMTs available to treat relapsing forms of multiple sclerosis (MS) 
in the US. MethOds: Adult patients with a claim for fingolimod, teriflunomide or 
dimethyl fumarate on or after September 22, 2010 (‘index’) were identified in the 
Truven Health MarketScan® databases. Patients had an MS diagnosis (ICD-9-CM 
340) in the 12 months prior to index, continuous enrollment 12 months pre- and 3 
months post-index and a confirmatory claim for their index drug. Demographic, 
clinical and severity characteristics were measured and compared in the 12 month 
baseline period. ResULts: A total of 3,379 patients were included, mean age 46.3 
(SD 10.5), 75.4% female. The majority (85.8%, n= 2,899) indexed on fingolimod, with 
10.0% (n= 339) indexing on teriflunomide and the remaining 4.2% (n= 141) indexing 
on dimethyl fumarate. Patients indexing on teriflunomide and dimethyl fumarate 
were significantly older than those indexing on fingolimod (50.0 [SD 9.6] and 48.1 
[SD 10.4] vs. 45.8 (SD 10.2), respectively, both p< 0.01). A greater proportion of patients 
indexing on teriflunomide had chronic pain, high blood pressure and high choles-
terol than those indexing on fingolimod (47.2% vs.40.8%, 30.4% vs. 19.7% and 24.5% 
vs. 15.8%, respectively, all p< 0.05) and a greater proportion of patients indexing on 
dimethyl fumarate had arthritis and thyroid disease than those indexing on fin-
golimod (13.5% vs. 6.9% and 13.5% vs. 8.1%, both p< 0.05). cOncLUsiOns: Factors 
in the decision to start disease modifying therapy with one of the oral medications 
can be complex. This study showed that older patients with more comorbid disease 
are being channeled to the two newest oral medications on the market.
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Objectives: Intrathecal drug therapy via implanted pump for treatment of spas-
ticity and chronic pain is highly varied and may have significant implications for 
patient outcomes. The objectives of this study were to: 1) characterize factors 
that influence real-world usage of these drugs, and 2) identify key differences 
and similarities in clinical practice, along with unmet needs across global mar-
kets. MethOds: A cohort of 96 health care providers (HCPs) was surveyed across 6 
countries, Canada (16), France (15), Italy (10), Germany (20), UK (15), and US (20). The 
HCPs included physicians and nurses caring for patients with intrathecal pumps 
across multiple specialties. ResULts: Compounded vs Manufacturer-prepared: 
While respondents cited continued need for compounded drugs (66%), comparable 
manufacturer-prepared drugs, if available, were preferred by at least 33% (highest 
in Germany, 45%), even at a higher procurement cost (20%). Over 25% respondents 
expressed concern over compounded drugs, including limited regulation, vari-
able efficacy, and potential for sterility issues. 1) Dosage: Depending on the drug, 
from 60% to 90% of respondents expressed interest in new manufacturer-prepared 
doses; 2) Packaging Format: Over 77% respondents preferred pre-filled syringes 
over ampules (18%) or vials (5%), largely due to ease of use and sterility. Despite this 
preference, 65% of respondents were concerned about the associated higher cost of 
prefilled syringes. cOncLUsiOns: This cross-sectional survey identified consist-
ent themes across the 6 markets. Unmet needs identified included opportunities 
for manufacturer-prepared drugs, new packaging forms, and new concentrations. 
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study was to estimate the proportion of cleft palate surgeries identified as secondary 
(or revision) in patients with a diagnosis of cleft palate only or cleft lip and palate. 
Additional objectives included identification and analysis of patient and hospital 
level characteristics. MethOds: The Kids’ Inpatient Database (KID), a nationally 
representative sample of pediatric inpatient visits, was used for this study. Years 
analyzed included 2003, 2006, and 2009. Subjects were identified by International 
Classification of Diseases Ninth Revision (ICD-9) diagnosis of cleft palate only or 
cleft lip and palate. Primary surgery was defined as a surgery before three years of 
age with the ICD-9 procedural code ‘Correction Cleft Palate.’ Secondary surgery was 
defined as a surgery at age three or older with any of the following ICD-9 procedural 
codes: ‘Correction Cleft Palate,’ ‘Revision Cleft Palate Repair,’ ‘Closure Fistula Mouth,’ 
or ‘Plastic Repair Palate.’ Hospital, patient, and clinical characteristics were also 
examined across cohorts. All costs were adjusted to 2009 dollars using the Consumer 
Price Index (CPI). ResULts: For the three years combined, 15,861 discharges for cleft 
palate repair were reported: 7,856 for CP only patients and 8,055 for CLP patients. 
Secondary surgery accounted for 28.1% (N= 2,193) of palate repairs performed in 
children with CP only, compared to 43.5% (N= 3,505) of palate repairs in children 
with CLP. Secondary surgery rates did not differ significantly across years. From 
2003-2009, CPI-adjusted costs decreased in all cohorts except secondary surgery in 
CP only patients. cOncLUsiOns: Secondary surgeries represent a significant por-
tion of cleft palate repairs performed in the United States. Children with cleft palate 
only have fewer secondary surgeries compared to those with cleft lip and palate.
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Prior Disease-MoDifyiNg Drug use aMoNg PaTieNTs WiTh MulTiPle 
sclerosis
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Objectives: To evaluate prior disease-modifying drug (DMD) use among currently 
treated and currently untreated multiple sclerosis (MS) patients. MethOds: A ran-
dom sample of MS patients (age > 18 years) from the National Health and Wellness 
Survey or Lightspeed Research panel completed an internet survey in November/
December 2012. The survey contained questions related to demographics, disease 
characteristics, and current and prior DMD use. The number and percentage of 
patients reporting prior DMD use by current therapy groups (self-injectable DMDs, 
infusion DMDs, oral DMDs, and not currently on DMD) is described. ResULts: 
There were 969 patients who completed the survey. Average age was 48.8 years (SD 
11.3), 82.9% were female and 737 (76.1%) were currently receiving DMD treatment 
[self-injectable: 576 (78.2%); infusion: 84 (11.4%); oral: 77 (10.4%)]; while 232 (23.9%) 
were currently untreated. Among patients currently treated with a self-injectable 
DMD, most patients were either on their first treatment (57.7%) or had prior use 
of 1 DMD (27.4%). For those currently treated with an infusion DMD, 42.9% had 
prior use of 1 DMD, 36.9% had prior use of 2 DMDs, and 17.9% had prior use of ≥ 3 
DMDs. For patients currently treated with an oral DMD, 27.3% had prior use of 1 
DMD, 32.5% had prior use of 2 DMDs, 32.5% had prior use of ≥ 3 DMDs, and 7.8% 
were initially treated with an oral DMD. For those not currently on a DMD, 34.9% 
were untreated, while 33.2%, 18.5%, and 13.4% had prior use of 1, 2, or ≥ 3 DMDs, 
respectively. cOncLUsiOns: In this sample of MS patients, 8.4% had never been 
treated with a DMD. Most patients initiated therapy with a self-injectable DMD, 
while patients currently treated with infusion and oral DMDs had prior use of 1 
or more DMDs.
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MeTa-aNalysis of aNasToMoTic leaK raTes folloWiNg haND-seWN 
suTure versus sTaPleD aNasToMoses DuriNg righT coloN surgery
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Objectives: Ileocolic anastomoses are commonly performed for right-sided colon 
cancer and Crohn’s disease. Anastomotic leak complications are a significant source 
of patient morbidity and mortality and have a major impact on health care costs. 
The objective of this analysis was to compare anastomotic leak rates following 
ileocolic anastomoses performed using mechanical stapling and hand-sewn suture 
techniques. MethOds: Pubmed, Embase, Cochrane Library and trial registries were 
searched for randomized controlled trials comparing hand-sewn and stapled ile-
ocolic anastomoses published between 1990 and December 2013. The odds ratio (OR) 
for overall anastomotic leak rate was calculated and then weighted and pooled in a 
meta-analysis with Mantel-Haenszel fixed-effect modeling with Chi square test for 
heterogeneity. ResULts: Eight studies with a total of 1,172 patients were included. 
Two studies were from Germany, 2 from Scotland, 1 from France, 1 from Japan, 1 from 
US and 1 was a global study with patients from US, UK and Canada. The median and 
average sample sizes across studies were 112 and 149 patients, respectively. Three 
studies were for Crohn’s disease, 3 were for colorectal cancer and 2 were for other 
diagnoses. There were 11 (2.31%) anastomotic leaks reported in 457 patients in the 
mechanically stapled group, and 44 (6.15%) leaks in 715 patients in the hand-sewn 
(sutures) group. At study level, the median leak rates in stapled and hand-sewn 
groups were 0.40% and 3.95%, respectively. Overall, the odds of anastomotic leaks 
were reduced to less than half with mechanical stapling compared to hand sewn 
techniques (pooled OR = 0.46; 95% CI = 0.24 to 0.89; p = 0.02). cOncLUsiOns: This 
meta-analysis of randomized controlled trials comparing hand-sewn with stapled 
ileocolic anastomoses demonstrates a significantly lower rate of anastomotic leak-
gery at age two or older with the ICD-9 procedural code for cleft lip repair. Additional 
characteristics examined across cohorts include length of stay and Consumer Price 
Index (CPI) adjusted charges. ResULts: A total of 8,385 discharges for cleft lip repair 
were reported. In CL patients secondary surgery represented 16.3% (N= 134), 14.2% 
(N= 105), and 15.1% (N= 129) of surgeries for 2003, 2006, and 2009, respectively. In CLP 
patients secondary surgery represented 25.7% (N= 511), 25.2% (N= 506), and 28.2% 
(N= 555) for 2003, 2006, and 2009, respectively. From 2003-2009, mean length of stay 
and CPI-adjusted costs decreased in all cohorts except secondary surgery in CL 
patients. cOncLUsiOns: One fourth of all children required secondary surgery. 
The proportion of secondary cleft lip surgery did not differ significantly across 
years. Once adjusted, costs have decreased for the majority of patients, a finding 
in contrast to previously published studies.
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hyPNoTics
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Objectives: This study investigated the effect of Medicare Part D on prescribing 
patterns and drug utilization of non-benzodiazepine sedative hypnotics. MethOds: 
Time-series analyses were conducted using data from National Ambulatory Medical 
Care Survey (NAMCS). Subjects were derived from US. outpatient visits between 2002 
and 2009 where the primary payment source was Medicare and at least one non-
benzodiazepine sedative hypnotic drug was prescribed. Data trends were graphically 
plotted and further analyzed using segmented regression to estimate the effects of 
the Medicare Part D on drug utilization. A weighted multivariate logistic regression 
was conducted to predict the maximum likelihood of prescribing pattern associated 
with patient and physician socioeconomic characteristics. All analyses utilized SAS 
PROC SURVEY applications to adjust for the complex sampling design employed 
by NAMCS database. ResULts: An estimated 31.52 million of Medicare beneficiar-
ies received at least one non-benzodiazepine prescription between 2002 and 2009 
during their outpatient visits. After Medicare part D in 2006, there was a notable 
increase (24%) in Medicare outpatient visits between 2006 and 2009. In the same 
time period, prescribing of non-benzodiazepine sedatives increased significantly 
by 46.3%. The results from segmented regression indicate that the implementation 
of Medicare Part D drug benefits has significantly increased the sedative utiliza-
tion in Medicare population (P= 0.0001). Multivariate logistic regression revealed 
that patient gender, geography, chronic condition, and physician specialty all play 
an important role in determining the utilization pattern of non-benzodiazepine 
sedatives. cOncLUsiOns: Our study indicated that the use of non-benzodiazepine 
hypnotics increased dramatically after Medicare Part D. Increased utilization may 
also be related to the switching effect from benzodiazepine formulary exclusion 
and/or antidepressant off-label use for insomnia pharmacotherapy. These findings 
show the importance of using data analysis to identify substantial consequences 
from policy implementation and the need to provide additional guidance to insurers 
on how to effectively monitor prescribing patterns.
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Objectives: To evaluate the burden of 30-day readmissions in adjunctively-treated 
patients with epilepsy. MethOds: The MarketScan®retrospective database (Jan-
2006 to Dec-2011) was used. Selected patients had: ≥ 1 diagnosis code for epilepsy 
(ICD-9 345.xx), age ≥ 18, ≥ 1 hospitalization (index), and received adjunctive AEDs 
during study period. Eligible patients had 60 days pre- and ≥ 365 days post-index 
continuous enrolment. Patients were stratified by type of hospitalization (all-cause 
or epilepsy-related) and by partial vs. generalized epilepsy diagnosis. Readmissions 
were defined as any hospitalization occurring < 30 days from the preceding hospi-
talization’s discharge date. ResULts: Of a total of 504,507 patients, 141,017 (19%; age 
51±17.6; 59% female, average follow-up 1,188 days) had ≥ 1 all-cause hospitalizations, 
and of these, 91,587 (65%) had an epilepsy-related admission, and 41,453 (29%) had 
≥ 1 all-cause 30-day readmissions. Forty-six percent of patients (8,955) had epilepsy-
related readmissions. Among patients with epilepsy-related hospitalizations, 19,115 
(21%) had ≥ 1 all-cause 30-day readmissions, 61% of whom (11,670) had epilepsy-
related readmissions. Partial epilepsy accounted for 9,882 (7%) of the total number 
of patients hospitalized (all-cause) during the study period; 100% of these patients 
had one or more epilepsy-related admissions. Among the hospitalized (all-cause) 
with POS, 1,729 (18%) had ≥ 1 all-cause readmissions, and of these 1,140 (66%) had ≥ 1 
epilepsy-related readmissions. Among POS patients with epilepsy-related hospitali-
zations, 1,502 (15%) had ≥ 1 all-cause readmissions, and of these 1,055 (70%) had ≥ 1 
epilepsy-related readmissions. cOncLUsiOns: In this study, approximately one in 
three patients with epilepsy hospitalized for any reason had a 30-day readmission, 
with approximately half of these patients presenting 30-day readmissions due to 
epilepsy. Approximately 60% of patients with an epilepsy-related admission had 
a 30-day readmission due to epilepsy. Patients with partial epilepsy had a greater 
burden of epilepsy-related hospitalizations and readmissions.
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Objectives: Children with cleft palate (CP) or cleft lip and palate (CLP) may require 
multiple surgeries to improve their appearance and function. The objective of this 
